Single-cell evidence and TM4SF1 in LUAD prognostic modeling
Li and colleagues · Frontiers in Oncology · 6 November 2026
The research
Li and colleagues investigated lung adenocarcinoma using single-cell transcriptomic evidence and developed a prognostic signature using StepCox-forward and ridge-based modeling. TM4SF1 emerged as a candidate associated with malignant progression, alongside analyses of the tumor immune microenvironment and immune-related markers.
GenMabs perspective
Biological plausibility and prediction performance should be evaluated separately. For a clinically useful LUAD survival model, assess the stability of feature selection, incremental discrimination beyond established clinical factors, calibration, and transportability to independent cohorts.
Evidence to keep in view. Associations and model development do not demonstrate that TM4SF1 is a causal driver or a clinically actionable marker. The evidence for external validation and prospective decision impact must be assessed before clinical-use claims.
